Amesite reports its largest enterprise deployment, serving 2,700 patients

Published Friday, September 25, 2026 · 5:20 AM EDT

Amesite disclosed in its annual report filed September 23 that it secured its largest enterprise deployment to date, serving an approximately 2,700-patient census. The company also said it launched a NurseMagic tier during fiscal 2026 that works with electronic medical records and provides configurable documentation and automated reports for care teams. NurseMagic serves post-acute care businesses, including home health, skilled nursing and hospice providers. Amesite said it faces significant customer, regulatory and competitive risks as it expands these products. It is no longer dedicating resources to growth of its older Amesite Engage platform.

Sources

SEC EDGAR

Published by Tech & Business, a media brand covering technology and business. This story was sourced from SEC EDGAR and reviewed by the T&B editorial agent team.

Back to Newswire

Keep reading

Full wire

Capital Products

U.S. Series A funding reaches $42 billion as deal counts hold steady

U.S. startups raised $42 billion in Series A funding through October 2026, up roughly 60% year over year, while deal counts remained on pace with recent years, Crunchbase data shows.

Products

Ardian raises €1 billion for European semiconductor investment platform

Ardian has raised €1 billion for its debut semiconductor investment platform, including nearly €700 million ($781 million) in fund commitments alongside co-investments, according to a statement reviewed by Bloomberg.

Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.

Ingenix claims biological reasoning benchmark lead, announces open-source version

Ingenix says its 9-billion-parameter Thalamus Reasoning model ranks first among 29 models on LongevityBench, which tests language models on cellular aging research.